Expressive Wealth LLC Buys Shares of 4,949 Merck & Co., Inc. $MRK

Expressive Wealth LLC bought a new stake in Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, Holdings Channel reports. The firm bought 4,949 shares of the company’s stock, valued at approximately $521,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. in the 4th quarter valued at about $25,000. High Note Wealth LLC lifted its holdings in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares during the last quarter. Tucker Asset Management LLC acquired a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $34,000. Entrust Financial LLC acquired a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $37,000. Finally, United Financial Planning Group LLC acquired a new position in shares of Merck & Co., Inc. in the 3rd quarter worth approximately $31,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Trading Down 2.2%

Shares of NYSE:MRK opened at $119.75 on Wednesday. Merck & Co., Inc. has a 52 week low of $75.40 and a 52 week high of $125.14. The company’s 50 day moving average is $116.13 and its two-hundred day moving average is $110.93. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The company has a market cap of $295.76 billion, a PE ratio of 33.73, a P/E/G ratio of 2.76 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the prior year, the firm posted $2.22 EPS. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities analysts predict that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s Keytruda combination with Padcev received support from Europe’s CHMP for certain bladder cancer patients, which could broaden use of one of Merck’s most important cancer franchises and support future revenue growth. Article: MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer
• Positive Sentiment: Merck also announced a regular third-quarter 2026 dividend, reinforcing its appeal as a large-cap healthcare income stock. Article: Merck Announces Third-Quarter 2026 Dividend
• Positive Sentiment: A separate collaboration announcement with Adcendo highlights continued external development activity around KEYTRUDA, keeping Merck’s immuno-oncology platform in the spotlight. Article: Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD
• Neutral Sentiment: Other articles mention Merck in the context of broader biotech and industry news, including Janux Therapeutics and a global IVP assay repository initiative, but these do not appear to be direct fundamental drivers for MRK shares. Article: Here’s Why You Should Add JANX Stock to Your Portfolio Now Article: Zifo, Pistoia Alliance, and Pharma Majors Launch Global IVP Assay Repository
• Negative Sentiment: A Minnesota jury found Merck liable in a mesothelioma-related talc lawsuit, renewing investor concerns about legal risks and potential future damages tied to the company’s legacy talc litigation. Article: Merck Talc Verdict Adds Fresh Liability Question For High Flying Shares

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Royal Bank Of Canada restated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. Wall Street Zen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. UBS Group raised their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Barclays started coverage on shares of Merck & Co., Inc. in a research report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price target for the company. Finally, Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.